IgM型原发浆细胞白血病2例

孙晶晶; 徐勇; 周东明; 关朝阳; 陈兵

doi:10.12354/j.issn.1000-8179.2021.20210911

IgM型原发浆细胞白血病2例

doi: 10.12354/j.issn.1000-8179.2021.20210911

孙晶晶^1,,
徐勇²,
周东明²,
关朝阳²,
陈兵^{1, 2, ,}

1.
南京医科大学鼓楼临床医学院血液科（南京市210008）
2.
南京大学医学院附属鼓楼医院血液科

详细信息

作者简介:
孙晶晶：专业方向为恶性血液病的诊治

通讯作者:
陈兵　chenbing2004@126.com

计量
- 文章访问数: 363
- HTML全文浏览量: 45
- PDF下载量: 54
- 被引次数: 0
出版历程
- 收稿日期: 2021-06-08
- 网络出版日期: 2021-08-30
- 刊出日期: 2021-09-30

摘要

- 原发浆细胞白血病 /
- IgM型 /
- 临床特征 /
- 维奈托克

HTML全文

参考文献(10)

[1]	De Larrea CF, Kyle RA, Durie BGM, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the international myeloma working group[J]. Leuke, 2013, 27(4):780-791.
[2]	Gundesen MT, Lund T, Moeller HEH, et al. Plasma cell leukemia: definition, presentation, and treatment[J]. Curr Oncol Rep, 2019, 21(1):8. doi: 10.1007/s11912-019-0754-x
[3]	Oka S, Yokote T, Akioka T, et al. Successful treatment of multi-agent chemotherapy with rituximab for IgM plasma cell leukemia[J]. Leuke Res, 2006, 30(12):1581-1583. doi: 10.1016/j.leukres.2006.02.012
[4]	Chhabra S, Jain S, Fowler A, et al. IgM myeloma with plasma cell leukemia: case report and literature review[J]. Ann Clin & Lab Sci, 2017, 47(5):611-619.
[5]	苗文春,蒋志相,朱卫国,等.IgM型原发性浆细胞白血病一例伴文献复习[J].浙江临床医学,2017,19(011):2144-2145.
[6]	Valliani S, Ali M, Mahmoo O, et al. Efficacy of venetoclax and dexamethasone in refractory IgM primary plasma cell leukemia with t (11; 14) and TP53 mutation: A case report and literature review[J]. Case Rep Hematol, 2020, 12(28):2020.
[7]	Girard LP, Soekojo CY, Ooi M, et al. Immunoglobulin M paraproteinaemias[J]. Cancers, 2020, 12(6):1688. doi: 10.3390/cancers12061688
[8]	Yu T, Xu Y, An G, et al. Primary plasma cell leukemia: real-world retrospective study of 46 patients from a single-center study in China[J]. Clin Lymph Myel & Leuke, 2020, 20(10):e652-e659.
[9]	Touzeau C, Maciag P, Amiot M, et al. Targeting Bcl-2 for the treatment of multiple myeloma[J]. Leukemia, 2018, 32(9):1899-1907. doi: 10.1038/s41375-018-0223-9
[10]	Nalghranyan S, Singh AP, Schinke C. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia[J]. Am J Hematol, 2020, 95(2):E34-E35.